Skip to main content

Advertisement

SpringerLink
Log in

Anti-cyclic citrullinated peptide (CCP) antibody in patients with wood-smoke-induced chronic obstructive pulmonary disease (COPD) without rheumatoid arthritis

  • Original Article
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Citrullination, a post-translational modification of proteins, is increased in inflammatory processes and is known to occur in smokers. It can induce anti-cyclic citrullinated peptide (CCP) antibodies, the most specific serologic marker for rheumatoid arthritis. Thus far, the incidence of autoimmunity in patients with wood-smoke-induced chronic obstructive pulmonary disease (COPD) resulting in anti-CCP production has not been examined. We hypothesise that anti-CCP antibody level in these patients should be higher than that in healthy subjects. A total of 112 non-rheumatoid arthritis patients, including 56 patients with wood-smoke-induced COPD and 56 patients with tobacco-induced COPD, and 56 healthy non-smoker controls were included. The serum anti-CCP antibody levels were measured and compared between the groups and against smoke exposure and clinical characteristics. The mean anti-CCP antibody levels in wood-smoke-induced COPD group were significantly higher than those in tobacco-induced COPD group (p = 0.03) and controls (p = 0.004). Furthermore, 8 (14.2 %) patients with wood-smoke-induced COPD, 4 (7.14 %) with tobacco-induced COPD and 2 (3.57 %) controls exceeded the conventional cut-off of anti-CCP antibody positivity. No relationship was found between the anti-CCP antibody level and age, gender, duration of disease, Pack-years of smoking, and duration of exposure to wood smoke. Moreover, correlations between anti-CCP antibodies and severity of airflow limitation, CAT scores, mMRC scores of dyspnoea, and GOLD staging of COPD severity were not significant. Wood-smoke-induced COPD could significantly increase the anti-CCP antibody level in non-rheumatoid arthritis patients when compared with that in patients with tobacco-induced COPD and healthy controls.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A et al (2013) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 187(4):347–365

    Article  CAS  PubMed  Google Scholar 

  2. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L et al (2004) The nature of small-airway obstruction in chronic pulmonary disease. N Engl J Med 350:2645–2653

    Article  CAS  PubMed  Google Scholar 

  3. Feghali-Bostwick CA, Gadgil AS, Otterbein LE, Pilewski JM, Stoner MW, Csizmadia E et al (2008) Autoantibodies in patients with chronic obstructive disease. Am J Respir Crit Care Med 177:156–163

    Article  PubMed Central  PubMed  Google Scholar 

  4. Cainelli F, Betterle C, Vento S (2004) Antinuclear antibodies are common in an infectious environment but do not predict systemic lupus erythematosus. Ann Rheum Dis 63:1707–1708

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Nunez B, Sauleda J, Anto JM, Julia MR, Orozco M, Monso E et al (2011) Anti-tissue antibodies are related to lung function in chronic obstructive lung disease. Am J Respir Crit Care Med 183:1025–1031

    Article  CAS  PubMed  Google Scholar 

  6. Taraseviciene-Stewart L, Scerbavicius R, Choe KH, Moore M, Sullivan A, Nicolls MR et al (2005) An animal model of autoimmune emphysema. Am J Respir Crit Care Med 171:734–742

    Article  PubMed  Google Scholar 

  7. Amson Y, Shoenfeld Y, Amital H (2010) Effect of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun 35:258–265

    Google Scholar 

  8. Makrygiannakis D, af Klint E, Lundberg IE, Lofberg R, Ulfgren AK, Klareskog L et al (2006) Citrullination is an inflammation-dependent process. Ann Rheum Dis 65:1219–1222

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Makrygiannakis D, Hermansson M, Ulfgren A-K, Nicolas AP, Zendman AJ, Eklund A et al (2008) Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increase citrullination in BAL cells. Ann Rheum Dis 67:1488–1492

    Article  CAS  PubMed  Google Scholar 

  10. Wood AM, de Pablo P, Bukley CD, Ahmed A, Stockley RA (2011) Smoke exposure as a determinant of autoantibody titre in α1-antitrypsin deficiency and COPD. Eur Respir J 37:32–38

    Article  CAS  PubMed  Google Scholar 

  11. Van Gaalen FA, Lin-Rasker SP, van Venrooij WJ, de Long BA, Breedveld FC, BAVerweij CL et al (2004) Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 50(3):709–715

    Article  PubMed  Google Scholar 

  12. Van Venrooj WJ, Hazes JMW, Visser H (2002) Anti-citrullinated protein/peptide antibody and its role in the diagnosis and prognosis of early rheumatoid arthritis. Neth J Med 60:383–388

    Google Scholar 

  13. Soderlin M, Petersson I, Bergman S, Svensson B (2011) Smoking at onset of rheumatoid arthritis (RA) and its effect on disease activity and functional status: experiences from BARFOT, a long-term observational study on early RA. Scand J Rheumatol 40(4):249–255

    Article  CAS  PubMed  Google Scholar 

  14. Ruiz-Esquide V, Gomera MJ, Peinado VI, Puerta JAG, Barbera JA, de Dios Canete J et al (2012) Anti-citrullinated peptide antibodies in the serum of heavy smokers without rheumatoid arthritis. A differential effect of chronic obstructive pulmonary disease? Clin Rheumatol 31(7):1047–1050

    Article  PubMed  Google Scholar 

  15. Salvi SS, Barnes PJ (2009) Chronic obstructive pulmonary disease in non-smokers. Lancet 374:733–743

    Article  PubMed  Google Scholar 

  16. Cell BR, Mac Nee W (2004) Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 23:932–946

    Article  Google Scholar 

  17. Jones PW, Harding P, Berry P, Wiklund I, Chen WH, Leidy NK (2009) Development and first validation of the COPD assessment test. Eur Respir J 34:648–654

    Article  CAS  PubMed  Google Scholar 

  18. Miravitalles M, Garcia-Sidro P, Fernandez-Nistal A, Buendia MJ, de los Monteros MJE, Molina J (2013) Course of COPD assessment test (CAT) and clinical COPD questionnaire (CCQ) scores during recovery from exacerbations of chronic obstructive pulmonary disease. Health Qual Life Outcome 11:147

    Article  Google Scholar 

  19. Mahler DA, Wells CK (1998) Evaluation of clinical methods for rating dyspnea. Chest 93:580–586

    Article  Google Scholar 

  20. Vossenaar ER, Zendman AJ, van Venrooji WJ, Pruijn GJ (2003) PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioassay 25:1106–1118

    Article  CAS  Google Scholar 

  21. Klareskog L, Stolt P, Lundberg K, lberg HK, Bengtsson C, Grunewald J et al (2006) Smoking may trigger HLA–DR (Shared Epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rh 54:38–46

    Article  CAS  Google Scholar 

  22. Mandl LA, Chibnik L, Schur P, Karlson EW (2005) Anti-cyclic citrullinated peptide (Anti-CCP) antibodies are strongly associated with risk of rheumatoid arthritis after adjusting for hormonal and behavioral factors. Arthritis Rheum 52(suppl.):S732

    Google Scholar 

  23. Lundstrom E, Kallberg H, Alfredsson L, Klareskog L, Padyukov L (2009) Gene–environment interaction between the DRB1 shared epitope and smoking in the risk of anti citrullinated protein antibody positive rheumatoid arthritis. Arthritis Rheum 60:1597–1603

    Article  PubMed  Google Scholar 

  24. Elkayan O, Segal R, Lidgi M, Caspi D (2006) Positive anti-cyclic citrullinated proteins and rheumatoid factor during active lung tuberculosis. Ann Rheum Dis 65:1110–1112

    Article  Google Scholar 

  25. Fischer A, Solomon JJ, du Bois RM, Deane KD, Olson AL, Fernandez-Perez ER et al (2012) Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease. Respir Med 106(7):1040–1047

    Article  PubMed Central  PubMed  Google Scholar 

  26. Rivera RM, Cosio MG, Ghezzo H, Salazar M, Perez-Padilla R (2008) Comparison of lung morphology in COPD secondary to cigarette and biomass smoke. Int J Tuberc Lung Dis 12:927–977

    Google Scholar 

  27. Ruiz-Esquide V, Sanmart R (2012) Tobacco and other environmental risk factors in rheumatoid arthritis. Reumatol Clin 8(6):342–350

    Article  PubMed  Google Scholar 

  28. Bergstro U, Jacobsson LTH, Nilsson JA, Berglund G, Turesson C (2011) Pulmonary dysfunction, smoking, socioeconomic status and the risk of developing rheumatoid arthritis. Rheumatology 50:2005–2013

    Article  Google Scholar 

  29. Roy K, Smith J, Kolsum U, Borrill Z, Vestbo J, Singh D (2009) COPD phenotype description using principal components analysis. Respir Res 10:41

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

The authors would like to thank the Deputy of Research and Technology, Kurdistan University of Medical Sciences, Sanandaj, Iran for their financial support. This study is financially supported by Medical Research Committee of Kurdistan University of Medical Sciences.

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Internal Medicine Department, School of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran

    Naseh Sigari & Nasrin Moghimi

  2. Kurdistan University of Medical Sciences, Sanandaj, Iran

    Farhad Saber Shahraki

  3. Pediatric Medicine Department, School of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran

    Shilan Mohammadi

  4. Department of Epidemiology and Biostatistics Kurdistan Research Center for Social Determinants of Health (KRCSDH), School of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran

    Daem Roshani

Authors
  1. Naseh Sigari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nasrin Moghimi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Farhad Saber Shahraki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shilan Mohammadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Daem Roshani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Naseh Sigari.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sigari, N., Moghimi, N., Shahraki, F.S. et al. Anti-cyclic citrullinated peptide (CCP) antibody in patients with wood-smoke-induced chronic obstructive pulmonary disease (COPD) without rheumatoid arthritis. Rheumatol Int 35, 85–91 (2015). https://doi.org/10.1007/s00296-014-3083-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-014-3083-2

Keywords

Search

Navigation